Paras Healthcare

Paras Healthcare Limited was founded in 1987 with a foundational vision to bridge the healthcare accessibility gap in semi-urban and regional markets. Over nearly four decades of operations, the company has evolved into the fifth-largest healthcare provider across North India, Bihar, and Jharkhand, establishing a robust operational footprint. Key historical milestones include the aggressive expansion of its bed capacity from 1,250 beds in March 2022 to 2,135 beds by March 2024, reflecting its rapid infrastructure scaling strategy.

The core business model centers on delivering multi-specialty tertiary care services through established hospital units operating under the Paras Health brand. The company offers a comprehensive range of advanced medical treatments, with specialized clinical focus areas including heart care, cancer treatment, brain and nerve care, digestive health, and bone and joint replacement services. These medical service lines are supported by advanced diagnostic and therapeutic infrastructure tailored to the specific healthcare demands of regional populations.

Targeting high-growth tier 2 and tier 3 cities, Paras Healthcare strategically captures underserved patient demographics where quality healthcare infrastructure remains scarce. The company maintains an institutionalized approach to clinical delivery, relying on a dedicated professional workforce comprising 1,091 doctors and 1,509 nurses as of March 31, 2024. This established medical team ensures high service stickiness, repeat patient inflow, and deep community trust across its operational clusters in states such as Haryana, Bihar, Uttar Pradesh, Rajasthan, Jharkhand, and Jammu and Kashmir.

From an operational scale perspective, the company manages eight major multi-specialty hospitals located in key urban-rural gateways including Gurugram, Patna, Darbhanga, Panchkula, Udaipur, Ranchi, Srinagar, and Kanpur. Internal clinical governance emphasizes strict nurse-to-bed ratios and standardized operating procedures to maintain clinical efficiency. While extensive R&D is less characteristic of regional hospital chains, Paras Healthcare continuously upgrades its medical technology stack, incorporating advanced robotic surgery suites, high-end linear accelerators for oncology, and digital hospital management systems to optimize clinical outcomes.

The leadership and promoter group bring extensive healthcare management experience, driving the organization's overarching mission of affordable healthcare delivery. Strategic expansion initiatives focus on deepening cluster penetration within existing North Indian geographies while selectively evaluating greenfield and brownfield hospital acquisitions. The management team aims to leverage institutional capital from the public markets to fund ongoing capital expenditure and reduce balance sheet leverage, ensuring long-term operational resilience and sustainable enterprise value creation.

The Paras Healthcare initial public offering is structured as a book-built issue totaling approximately ₹1,450 crores. The issue comprises a fresh issuance of equity shares aggregating up to ₹500 crores and an offer for sale (OFS) aggregating up to ₹950 crores by existing shareholders. The price band for the equity shares is fixed between ₹660 and ₹693 per share, with a face value of ₹1 per equity share. The IPO opened for subscription on October 21, 2026, and closed on October 23, 2026, with the final listing scheduled on the BSE and NSE on October 28, 2026, following the completion of the basis of allotment and refund processing.

The net proceeds derived from the fresh issue component are primarily earmarked to fund strategic corporate objectives, including debt prepayment and servicing, capital expenditure for expanding existing hospital infrastructure, funding working capital requirements, and general corporate purposes. By allocating fresh capital toward balance sheet optimization and facility expansion, the company intends to lower its borrowing costs and enhance its asset turnover ratios across its regional hospital network.

Financially, Paras Healthcare demonstrates a mixed historical trajectory reflecting rapid capacity expansion and associated initial gestation costs. The company reported basic and diluted earnings per share (EPS) of negative ₹5.94 for Fiscal 2025, which recovered to positive ₹4.34 in Fiscal 2026 as newly operational hospital units achieved critical occupancy thresholds and improved operating leverage. Revenue growth has tracked the expansion of operational bed capacity from 1,250 beds in 2022 to over 2,135 beds in recent fiscal periods, though bottom-line profitability has been impacted by high initial capital depreciation and interest burdens.

In terms of peer valuation benchmarking, Paras Healthcare trades at distinct valuation multiples compared to established large-cap hospital chains like Apollo Hospitals, Max Healthcare, and Medanta, as well as mid-sized peers such as Yatharth Hospital. For Fiscal 2026, the company's reported EPS of ₹4.34 positions its valuation within a speculative band relative to sector leaders boasting double-digit EPS figures. Return metrics such as Return on Equity (ROE) and Return on Capital Employed (ROCE) have experienced near-term dilution due to heavy investments in greenfield hospital assets that are undergoing gestation phases.

Key investment highlights include the promoter group's strategic focus on underserved tier 2 and tier 3 healthcare markets in North India, which benefit from strong secular tailwinds, rising disposable incomes, and increasing health insurance penetration. Furthermore, the fresh issue portion injects direct growth capital into the enterprise. However, investor participation must be weighed against notable risks, including high geographic concentration in North India, intense competition from established regional and national hospital chains, regulatory pricing pressures on healthcare services, and the execution risk associated with ramping up new hospital units to optimal bed occupancy rates.

Market sentiment surrounding the IPO, as reflected in the grey market premium (GMP) hovering around ₹13 (representing an estimated marginal listing gain of approximately 1.88%), indicates cautious investor participation. Subscription data reveals moderate institutional interest led by QIB demand at 3.09x and retail participation at 1.96x, contrasted by softer HNI subscription at 0.64x. This tepid grey market baseline underscores a balanced market regime where investors are closely scrutinizing near-term profitability turnarounds and valuation justifications before committing capital to regional healthcare plays.